What Causes AIDP? Understanding the Immune Response
At a Glance
AIDP usually develops after a respiratory or gastrointestinal infection when the immune system mistakenly attacks the protective myelin coating around peripheral nerves. Some people never identify a preceding illness, and AIDP is not directly inherited or caused by anything they did.
In this answer
4 sections
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is caused by a misdirected immune response, typically following a recent, everyday infection. When you contract a common respiratory virus or stomach bug, your immune system mounts a defense to fight it off. In people who develop AIDP, the immune system becomes confused and accidentally attacks the myelin sheath—the protective coating around peripheral nerves—even after the original infection is gone [1]. This means you didn’t “catch” AIDP; rather, your body’s natural defense mechanism made a mistaken identity error following an illness [1].
It is important to note that a substantial minority of people with AIDP never identify a preceding illness, either because the infection was very mild, asymptomatic, or simply unknown [2]. Not knowing the specific trigger is normal and usually does not change your acute medical treatment or your chances of recovery.
(Safety Note: If you have newly diagnosed or suspected AIDP, weakness can progress rapidly. Seek emergency medical care immediately for new or worsening breathing difficulty, trouble swallowing, choking, rapidly worsening weakness, or fainting.)
Understanding the Terminology: GBS vs. AIDP vs. AMAN
AIDP is the most common subtype of Guillain-Barré Syndrome (GBS) in Western countries. GBS is a broad umbrella term for conditions where the immune system attacks the peripheral nerves. While AIDP involves an attack on the myelin sheath (demyelination), another common subtype called AMAN (acute motor axonal neuropathy) primarily involves an attack directly on the nerve fibers (axons) [1][3]. Research into the exact causes often looks at GBS as a whole, though certain triggers are more closely linked to specific subtypes.
One Proposed Mechanism: Molecular Mimicry
A leading theory for how infections trick the immune system into causing GBS is a process called molecular mimicry [4]. This mechanism is very well-established for the AMAN subtype and is considered one likely proposed mechanism for some cases of AIDP, though the exact biology of AIDP is complex and still being actively researched [5].
To understand molecular mimicry, imagine that germs have a specific uniform (surface molecules) that your immune system learns to recognize and attack. In some cases, the molecules on the surface of the invading bacteria or virus look almost identical to the molecules on your own nerve cells [4].
When your immune system builds custom defenses—such as antibodies (specialized targeting proteins) and white blood cells—these defenses circulate in your blood. During an inflammatory response, the blood-nerve barrier (a protective filter for your nerves) can become more permeable, allowing these immune elements to cross into the nerve area [6]. Because of the molecular resemblance, antibodies, specialized white blood cells (like T cells and macrophages), and immune proteins called complement mistakenly attack the myelin sheath, stripping it away and slowing or blocking the nerve signals [1][7].
Common Preceding Events
Research shows that roughly two-thirds of people with GBS report having had an illness in the weeks before their neurological symptoms began [2]. Recognized associations include:
- Respiratory Infections: Illnesses affecting the lungs or throat are frequently reported triggers and are often linked to the AIDP subtype in clinical studies [2][8]. These include common colds, influenza, Mycoplasma pneumoniae (a bacteria), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and SARS-CoV-2 (the virus that causes COVID-19) [5][9].
- Gastrointestinal Infections: Stomach bugs, particularly those caused by the bacteria Campylobacter jejuni (often from undercooked poultry), are well-established triggers [4][10]. While C. jejuni is most strongly linked to the AMAN subtype, it remains a recognized trigger across the GBS spectrum [11][8].
- Other Viruses: Outbreaks of the Zika virus have been strongly associated with surges in AIDP cases [12]. Hepatitis E (a liver virus) is also a reported trigger [13].
- Surgery or Trauma: Surgery has been reported in rare cases before the onset of GBS, though causal relationships are uncertain and physical trauma is not an established routine trigger [14].
- Vaccinations: Severe immune reactions following vaccines are extremely rare [15]. The risk of developing GBS varies by the specific vaccine, the product platform, and the season. Generally, public health data shows that the risk of developing GBS from an actual infection (like influenza or COVID-19) is higher than the risk from the vaccine protecting against it [9]. However, having GBS within 6 weeks of a prior flu vaccine is considered a precaution for future flu shots; you should always discuss your specific medical history with your doctor.
Why Did This Happen to Me?
A very common question patients ask is why they developed AIDP when millions of other people get the exact same cold or stomach bug and recover perfectly.
The answer is that an infection alone is not enough to cause AIDP [16]. For example, only a very small proportion of people infected with Campylobacter jejuni ever develop GBS [16]. Researchers believe it requires a specific combination of factors: a specific strain of the virus or bacteria, combined with your unique immune system variations [17][4].
While genetic differences in how your immune system responds to threats may influence your susceptibility, AIDP is generally a sporadic event, not a disease directly inherited from your parents [17]. There is no evidence that you did anything to cause this illness.
Common questions in this guide
What usually causes AIDP?
How can an infection lead to AIDP?
Which infections are linked to AIDP?
Can a vaccine cause AIDP?
Why did I develop AIDP when others recovered from the same infection?
Which AIDP symptoms require emergency care?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Get notified when new evidence is published on Acute inflammatory demyelinating polyradiculoneuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my specific symptoms and history, would testing for a past infection change my current treatment plan or how you monitor my recovery?
- 2.Do my current symptoms require closer hospital monitoring, and what specific physical changes should make me call emergency services?
- 3.Are there any specific vaccines I should avoid or delay based on the timing of my AIDP onset, and which ones are safe for me to receive?
- 4.How confident are we in the AIDP subtype diagnosis versus other forms of GBS, and does that subtype change my expected recovery timeline?
References
References (17)
- 1
[Pathology of the Peripheral Nervous System in Guillain-Barré Syndrome].
Nakano Y, Kanda T
Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(11)):1329-39 doi:10.11477/mf.1416200303.
PMID: 26560948 - 2
Guillain-Barré syndrome in southern China: retrospective analysis of hospitalised patients from 14 provinces in the area south of the Huaihe River.
Liu S, Xiao Z, Lou M, et al.
Journal of neurology, neurosurgery, and psychiatry 2018; (89(6)):618-626 doi:10.1136/jnnp-2017-316930.
PMID: 29326294 - 3
Guillain-Barré Syndrome.
Kaida K
Advances in experimental medicine and biology 2019; (1190()):323-331 doi:10.1007/978-981-32-9636-7_20.
PMID: 31760653 - 4
An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model.
Brooks PT, Bell JA, Bejcek CE, et al.
Journal of neuroimmunology 2019; (337()):577048 doi:10.1016/j.jneuroim.2019.577048.
PMID: 31678855 - 5
Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates.
Finsterer J
International journal of molecular sciences 2022; (23(22)) doi:10.3390/ijms232214222.
PMID: 36430700 - 6
The pathogenic relevance of αM-integrin in Guillain-Barré syndrome.
Dong C, Palladino SP, Helton ES, Ubogu EE
Acta neuropathologica 2016; (132(5)):739-752 doi:10.1007/s00401-016-1599-0.
PMID: 27460017 - 7
Peripheral nerve-targeting and pain-promoting transcriptomic signatures in early Guillain-Barré syndrome.
O'Brien JA, Lesnak JB, Sankaranarayanan I, et al.
bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.09.24.678413.
PMID: 41040175 - 8
How Different is AMAN from AIDP in Childhood GBS? A Prospective Study from North India.
Gupta PK, Singhi P, Singhi S, et al.
Indian journal of pediatrics 2019; (86(4)):329-334 doi:10.1007/s12098-018-2835-5.
PMID: 30637680 - 9
Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis.
Palaiodimou L, Stefanou MI, Katsanos AH, et al.
European journal of neurology 2021; (28(10)):3517-3529 doi:10.1111/ene.14860.
PMID: 33837630 - 10
Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies.
Koga M, Gilbert M, Li J, Yuki N
PloS one 2015; (10(4)):e0124004 doi:10.1371/journal.pone.0124004.
PMID: 25867522 - 11
Campylobacter jejuni Infection, Anti-Ganglioside Antibodies, and Neuropathy.
Latov N
Microorganisms 2022; (10(11)) doi:10.3390/microorganisms10112139.
PMID: 36363731 - 12
Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia.
Parra B, Lizarazo J, Jiménez-Arango JA, et al.
The New England journal of medicine 2016; (375(16)):1513-1523 doi:10.1056/NEJMoa1605564.
PMID: 27705091 - 13
Hepatitis E virus and neurological disorders.
Mclean BN, Gulliver J, Dalton HR
Practical neurology 2017; (17(4)):282-288 doi:10.1136/practneurol-2016-001588.
PMID: 28647707 - 14
Axonal variants of Guillain-Barré syndrome: an update.
Shang P, Zhu M, Wang Y, et al.
Journal of neurology 2021; (268(7)):2402-2419 doi:10.1007/s00415-020-09742-2.
PMID: 32140865 - 15
Guillain-Barré Syndrome Associated with COVID-19 Vaccination.
Shao SC, Wang CH, Chang KC, et al.
Emerging infectious diseases 2021; (27(12)):3175-3178 doi:10.3201/eid2712.211634.
PMID: 34648420 - 16
Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.
Jasti AK, Selmi C, Sarmiento-Monroy JC, et al.
Expert review of clinical immunology 2016; (12(11)):1175-1189 doi:10.1080/1744666X.2016.1193006.
PMID: 27292311 - 17
Genetic basis of Guillain-Barre syndrome.
Khanmohammadi S, Malekpour M, Jabbari P, Rezaei N
Journal of neuroimmunology 2021; (358()):577651 doi:10.1016/j.jneuroim.2021.577651.
PMID: 34246981
This page explains proposed causes and triggers of AIDP for informational purposes only and does not constitute medical advice. Because weakness can progress quickly, seek emergency care for new breathing or swallowing problems, choking, fainting, or rapidly worsening weakness.